Exchange: NASDAQ·Updated 01:20 AM EDT
NTLA logo

NTLA Intellia Therapeutics Inc

$12.78
$0.10
(0.79%)
Overnight
Prev Close $12.68
Reported EarningsAug 6
Mkt Cap$1.79B
Vol3M

About NTLA

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
31

Bearish Sentiment

How do you feel about NTLA?

Advertisement|Remove ads.